Skip to content
VuFind
Advanced
  • Cediranib in combination with...
  • Cite this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
QR Code

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study

Bibliographic Details
Main Authors: Hyams, D., Chan, Arlene, de Oliveira, C., Snyder, R., Vinholes, J., Audeh, M W., Alencar, V., Lombard, J., Mookerjee, B., Xu, J., Brown, K., Klein, P.
Format: Journal Article
Published: Springer Science + Business Media 2013
Online Access:http://hdl.handle.net/20.500.11937/33934
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://hdl.handle.net/20.500.11937/33934

Similar Items

  • Fulvestrant for the treatment of advanced breast cancer
    by: Blackburn, Sophie A., et al.
    Published: (2018)
  • Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer
    by: Robertson, John F.R., et al.
    Published: (2018)
  • Capecitabine and vinorelbine in metastatic breast cancer
    by: Chan, Arlene, et al.
    Published: (2009)
  • TILs in metastatic breast cancer—no surprises, but more questions
    by: Chan, Arlene
    Published: (2017)
  • Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    by: Robertson, John F.R., et al.
    Published: (2017)

Search Options

  • Advanced Search

Find More

  • Browse the Catalog

Need Help?

  • Search Tips